1. In this retrospective analysis, symptom and viral rebound occurred in almost one-third of coronavirus disease 2019 (COVID-19) patients that did not receive any antiviral treatment. 2. While recurrent symptom and viral rebound were common, the combination of symptom and viral rebound was rare. Evidence Rating Level: 2 (Good) Study Rundown: Clinical relapse has been
The U.S. National Institutes of Health (NIH) is conducting a multi-site clinical trial to evaluate Shionogi & Co.’s Xocova COVID-19 antiviral drug to determine its effectiveness in improving care for afflicted individuals.
PETALING JAYA: Those aged 60 and above can receive a second Covid-19 vaccine booster dose voluntarily four to six months after their first booster, says Khairy Jamaluddin.
Merck & Co Inc and partner Ridgeback Biotherapeutics said on Friday six lab studies showed their experimental oral COVID-19 drug molnupiravir was active against the fast-spreading Omicron variant.